Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phosphatase in the Treatment of Patients With Sepsis-Associated Acute Kidney Injury
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Ilofotase alfa (Primary)
- Indications Acute kidney injury
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms STOP-AKI
- Sponsors AM-Pharma
- 24 Oct 2018 Results published in the JAMA: the Journal of the American Medical Association
- 24 Oct 2018 Primary endpoint has not been met. (Measured creatinine clearance (based on urine volume and creatinine concentrations)), according to an AM-Pharma media release.
- 24 Oct 2018 According to an AM-Pharma media release, results from this study will be presented at the European Society of Intensive Care Medicine (ESICM) and at the American Society of Nephrology Kidney Week (Oct 2018).